The estimated Net Worth of Benjamin Looker is at least $192 ezer dollars as of 19 April 2023. Mr Looker owns over 1,290 units of Esperion Therapeutics stock worth over $145,574 and over the last 4 years he sold ESPR stock worth over $46,067.
Mr has made over 2 trades of the Esperion Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,290 units of ESPR stock worth $1,638 on 19 April 2023.
The largest trade he's ever made was selling 6,347 units of Esperion Therapeutics stock on 18 January 2023 worth over $44,429. On average, Mr trades about 955 units every 11 days since 2021. As of 19 April 2023 he still owns at least 83,663 units of Esperion Therapeutics stock.
You can see the complete history of Mr Looker stock trades at the bottom of the page.
Benjamin O. Looker is the Gen. Counsel at Esperion Therapeutics.
Mr Looker is 39, he's been the Gen. Counsel of Esperion Therapeutics since . There are 13 older and 1 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Benjamin's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... és Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: